Complain about a product or service

Public Citizen Seeks Ban On Orlistat

Says "Fat Blocker" Could Contribute to Colon Cancer

April 11, 2006

• Degree of Obesity Raises Risk of Stroke • Study: Calorie Postings On Fast Food Menus Help Kids • Pros and Cons of Gastric Bypass Surgery Charted • Weight Watchers Says Jenny Craig Too Big for its Britches • FTC Wins Case Against Marketers of Unproven Weight-Loss Products • Sedentary TV Time May Cut Life Short • Holistic Approach Touted For Those Who Can't Handle Diets • Eating Healthier On A Budget • Researchers Link Proximity to Convenience Stores with Obesity • Less TV Viewing Equals More Calories Burned • Getting A 'Head Start' On Obesity Prevention • Study: Weight Loss Proves Effective Cure For Sleep Apnea • Lower Smoking Rates Offset by Increased Obesity • CSPI: Nickelodeon Ad Content High in Junk Food • CSPI Gives Movie Popcorn Two Thumbs Down • Obesity Causes Over 124,000 New Cancers A Year In Europe • Exercise Minimizes Weight Regain, Study Says • CSPI Slams Domino's New Pasta As Unhealthy 'Food Porn' • FDA Conducting Safety Review Of Weight Loss Drug • Obesity Costs U.S. About $147 Billion Annually • New Insights Gained Into Causes Of Anorexia • CDC Launches Obesity Website • Modest Exercise Can Reduce Negative Effects of Belly Fat • Keep The Faith and Lose The Weight? • Families That Eat Together Means Kids Eating Better • New Factor in Teen Obesity: Parents • Possible Drug Target Found for Obesity Treatment • Weight Management Requires "Lifelong Commitment" • Obama Urged to Tackle Obesity • 5 Tips for Eating Right in 2009 • "All You Can Eat" A Ticket to Obesity • Sour Economy May Affect Eating Habits • Fast Food Has Fewer Calories Than Traditional Restaurant Meals --- • Weight Loss News • Childhood Obesity

Public Citizen is asking the U.S. Food and Drug Administration to immediately pull the prescription version of Xenical (orlistat) because the Roche Pharmaceuticals "fat blocker" could contribute to colon cancer.

The drug has been known to cause a significant increase in aberrant crypt foci, which are widely believed to be a precursor to colon cancer.

Last week, the FDA sent an "approvable" letter concerning the over-the-counter (OTC) version of orlistat to GlaxoSmithKline. Despite safety concerns, if GlaxoSmithKline meets the conditions set by the FDA -- conditions that have not been made public -- this would make the drug eligible for final approval for OTC sales.

Public Citizen said its petition is based on findings from the pharmacology review of Roche’s own data and a recent independent confirmation that orlistat causes ACF in the colon of rats.

There is a large amount of scientific literature that acknowledges the importance of ACF as the earliest identifiable neoplastic colonic lesion and a putative precursor of colon cancer.

The FDA’s own 1997 review of orlistat indicated a concern with colonic cell proliferation, and the drug was not initially approved by the FDA because of clinical trials that found a four- to seven-fold increased risk of getting breast cancer while taking orlistat.

In addition to cancer concerns, the group says adverse events for patients taking orlistat include a cluster of gastrointestinal symptoms and a loss of fat-soluble vitamins, including beta-carotene and vitamins A, D, E and K.

Orlistat’s efficacy has also been called into question because of two recently published clinical trials that showed only a 2.8 percent difference in weight loss after four years between patients taking orlistat and those on placebo.

"The failure to ban the prescription version of this drug or, worse, to make it much more widely available by allowing OTC sales, is a decision that is likely to increase cancer incidence," said Dr. Sidney Wolfe, director of Public Citizen’s Health Research Group.

Public Citizen is joined in the petition by two professors of pathology at Case Western Reserve School of Medicine, Dr. Theresa Pretlow and Dr. Thomas Pretlow, who are both experts on ACF’s link to colorectal cancer. Their work on this topic has been largely funded by the National Cancer Institute, whose director is now acting FDA commissioner.

"The FDA should not allow a drug … to remain on the market for the long-term treatment of a non-lethal condition when it combines so little efficacy coupled with a still unresolved potential to cause breast and colon cancer," says the 12-page petition. "[The] FDA is now considering increasing the number of people exposed to the drug by allowing OTC use. There is no scientific justification for this decision."

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Follow us on Twitter.